^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    JAK2 mutation

    i
    Other names: JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2
    Entrez ID:
    3717
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia (NCT02257138)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/08/2024
    Initiation :
    02/12/2015
    Primary completion :
    03/19/2021
    Completion :
    03/19/2021
    JAK2
    |
    JAK2 mutation
    |
    azacitidine • Jakafi (ruxolitinib) • decitabine
    A Study of LY2784544 in Participants With Myeloproliferative Neoplasms (NCT01594723)
    Phase 2
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    03/21/2024
    Initiation :
    05/22/2012
    Primary completion :
    03/20/2015
    Completion :
    12/01/2024
    JAK2
    |
    JAK2 mutation • JAK2 V617F
    |
    gandotinib (LY 2784544)
    Ruxolitinib in Thrombocythemia and Polycythemia Vera (NCT04644211)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    03/08/2024
    Initiation :
    03/21/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    JAK2
    |
    JAK2 mutation
    |
    Jakafi (ruxolitinib)
    UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia (NCT03913026)
    Phase 2
    Ciusss de L'Est de l'Île de Montréal
    Active, not recruiting
    Last update posted :
    02/16/2024
    Initiation :
    04/01/2019
    Primary completion :
    10/01/2024
    Completion :
    10/01/2027
    TP53 • FLT3 • JAK2 • HLA-DRB1 • CD34
    |
    TP53 mutation • FLT3 mutation • RAS mutation • JAK2 mutation
    |
    cyclophosphamide • Zemcelpro (dorocubicel)
    A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (AALL1521) (NCT02723994)
    Phase 2
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    01/12/2024
    Initiation :
    09/30/2016
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3
    |
    CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion
    |
    cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Erwinase (erwinia asparaginase)
    Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (NCT01895842)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    11/29/2023
    Initiation :
    02/01/2014
    Primary completion :
    04/02/2019
    Completion :
    04/02/2019
    JAK2 • NFKB1
    |
    JAK2 mutation
    |
    Jakafi (ruxolitinib)
    Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia (NCT03571321)
    Phase 1
    University of Chicago
    Recruiting
    Last update posted :
    11/29/2023
    Initiation :
    05/28/2019
    Primary completion :
    09/01/2026
    Completion :
    09/05/2027
    JAK2 • CRLF2 • IL7R • SH2B3
    |
    CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 rearrangement • SH2B3 deletion
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • cyclophosphamide intravenous
    Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders (NCT03801434)
    Phase 2
    William Shomali
    Recruiting
    Last update posted :
    11/02/2023
    Initiation :
    11/15/2019
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    JAK2 • ETV6 • PCM1
    |
    JAK2 mutation • JAK2 rearrangement
    |
    Jakafi (ruxolitinib)
    A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET (EXCEED ET) (NCT05482971)
    Phase 2
    PharmaEssentia
    Recruiting
    Last update posted :
    10/03/2023
    Initiation :
    09/29/2022
    Primary completion :
    07/29/2024
    Completion :
    12/31/2026
    JAK2
    |
    JAK2 mutation
    |
    Besremi (ropeginterferon alfa-2b-njft)
    Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis (NCT04217993)
    Phase 2
    Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    Completed
    Last update posted :
    04/20/2023
    Initiation :
    01/07/2020
    Primary completion :
    08/03/2022
    Completion :
    08/03/2022
    JAK2
    |
    JAK2 mutation
    |
    Jakafi (ruxolitinib)